-
Je něco špatně v tomto záznamu ?
COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information
D. Mauri, K. Kamposioras, L. Tsali, M. Dambrosio, B. De Bari, N. Hindi, C. Salembier, J. Nixon, T. Dimitrios, F. Alongi, H. Hameed, A. Valachis, K. Papadimitriou, S. Corradini, L. Popovic, J. Kopecky, A. Rodriguez, K. Antunac, J. Yi, J. Lovey, P....
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články
- MeSH
- COVID-19 * epidemiologie prevence a kontrola MeSH
- jazyk (prostředek komunikace) MeSH
- lidé MeSH
- nádory * MeSH
- vakcinace MeSH
- vakcíny proti COVID-19 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. METHODS: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. RESULTS: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. CONCLUSION: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
Acıbadem University Faculty of Medicine Turkey
Beatson West of Scotland Cancer Center Strathclyde University Glasgow UK
Cell Biologist CEO Bladder Cancer Oslo Norway
Chairmen of the Board Young Saving Association Turkey
Department Biomedical Sciences and Medicine University of Algarve Faro Portugal
Department for Radiosurgery and SBRT Clinical center of Serbia Belgrade Serbia
Department Medical Oncology Bank of Cyprus Oncology Centre Nicosia Cyprus
Department Medical Oncology Berat Regional Hospital Berat Albania
Department Medical Oncology Clinica San Carlo Paderno Dugnano Milano Italy
Department Medical Oncology Escola Paulista de Medicina Federal University of São Paulo Brazil
Department Medical Oncology Faculty of Medicine and Health Örebro University Örebro Antonios Sweden
Department Medical Oncology Fundación Jimenez Díaz University Hospital Madrid Spain
Department Medical Oncology Institute of Oncology Ljubljana Slovenia
Department Medical Oncology Oncology Institute of Vojvodina University of Novi Sad Serbia
Department Medical Oncology Rooshana Cancer Center Tehran Iran
Department Medical Oncology The Christie NHS Foundation Trust Manchester UK
Department Medical Oncology University Hospital of Ioannina Ioannina Greece
Department of Medical Oncology and Hematology Wilhelminenspital Vienna Austria
Department of Medical Oncology University Hospital of Antwerp Antwerp Belgium
Department Oncology and Radiotherapy Charles University Hradec Králové Prague Czech Republic
Department Radiation Oncology Institute of Oncology Ljubljana Slovenia
Department Radiation Oncology Royal Medical Service Amman Jordan
Department Radiation Oncology University Hospital LMU Munich Germany
Department Radiation Oncology University Hospital of Heraklion Crete Greece
ECPC Partneships and Communication Officer Belgium
Matsudo City General Hospital Chiba Japan
Medical Oncology Auckland Regional Cancer and Blood Service Auckland New Zealand
Medical Oncology Instituto Alexander Fleming in Buenos Aires Buenos Aires Argentina
National Institute of Oncology Semmelweis University Budapest Hungary
PACMeR Evidence Based Medicine Athens Greece
Radiation Oncology Department Europe Hospitals Brussels Belgium
Radiation Therapy Unit University Hospital Center Mother Teresa Tirana Albania
Radioterapia Oncologica Fondazione Policlinico A Gemelli IRCCS Rome Italy
Service de Radio Oncologie Neuchâtel Hôpital Network La Chaux de Fonds Switzerland
Service de Radiothérapie Oncologique GHT Grand Paris Nord Est G H 1 Le Raincy Montfermeil France
Service Radio Oncologie Neuchâtel Hôpital Network La Chaux de Fonds Switzerland
The Christie NHS Foundation Trust Manchester UK
The Christie NHS Foundation Trust Manchester UK The Christie\'s Hospital Manchester UK
UCSD Blood and Marrow Transplant Program UCSD Moores Cancer Center La Jolla CA USA
University Hospital for Tumors Sestre Milosrdnice University Hospital Center Zagreb Croatia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019589
- 003
- CZ-PrNML
- 005
- 20220804135811.0
- 007
- ta
- 008
- 220720s2022 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1574887116666211028145848 $2 doi
- 035 __
- $a (PubMed)34967300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Mauri, Davide $u Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
- 245 10
- $a COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information / $c D. Mauri, K. Kamposioras, L. Tsali, M. Dambrosio, B. De Bari, N. Hindi, C. Salembier, J. Nixon, T. Dimitrios, F. Alongi, H. Hameed, A. Valachis, K. Papadimitriou, S. Corradini, L. Popovic, J. Kopecky, A. Rodriguez, K. Antunac, J. Yi, J. Lovey, P. Strojan, H. Saraireh, R. Røtterud, M. Chojnacka, SC. Olalla, N. Chilingirova, RA. De Mello, GA. Amaral, F. Arbabi, R. Vidra, E. Rapushi, D. Takeuchi, C. Christopoulos, I. Ivanova, I. Djan, B. Petricevic, F. Cellini, I. Mihaylova, ND. Plavetic, CG. Kuhar, E. Takeuchi, P. Kountourakis, P. Ntellas, I. Gazouli, S. Gkoura, S. Yuce, Ö. Er, C. Yasmina, G. Kumaran, O. Spahiu, A. Yusuf, P. Gono, K. Apostolidis, M. Tolia
- 520 9_
- $a BACKGROUND: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. METHODS: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. RESULTS: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. CONCLUSION: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
- 650 12
- $a COVID-19 $x epidemiologie $x prevence a kontrola $7 D000086382
- 650 _2
- $a vakcíny proti COVID-19 $7 D000086663
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jazyk (prostředek komunikace) $7 D007802
- 650 12
- $a nádory $7 D009369
- 650 _2
- $a vakcinace $7 D014611
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kamposioras, Konstantinos $u Department. Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- 700 1_
- $a Tsali, Lampriani $u PACMeR Evidence Based Medicine, Athens, Greece
- 700 1_
- $a Dambrosio, Mario $u Department. Medical Oncology, Clinica San Carlo, Paderno Dugnano, Milano Italy
- 700 1_
- $a De Bari, Berardino $u Service Radio-Oncologie Neuchâtel Hôpital Network, La Chaux-de-Fonds, Switzerland
- 700 1_
- $a Hindi, Nadia $u Department. Medical Oncology, Fundación Jimenez Díaz University Hospital, Madrid, Spain
- 700 1_
- $a Salembier, Carl $u Radiation Oncology Department, Europe Hospitals, Brussels, Belgium
- 700 1_
- $a Nixon, Joanna $u Beatson West of Scotland Cancer Center, Strathclyde University, Glasgow, UK
- 700 1_
- $a Dimitrios, Tzachanis $u UCSD Blood and Marrow Transplant Program, UCSD/Moores Cancer Center, La Jolla, CA, USA
- 700 1_
- $a Alongi, Flippo $u Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria, Negrar-Verona,University of Brescia, Verona, Italy
- 700 1_
- $a Hameed, Hassan $u The Christie NHS Foundation Trust, Manchester UK, The Christie\'s Hospital, Manchester, UK
- 700 1_
- $a Valachis, Antonios $u Department Medical Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Antonios, Sweden
- 700 1_
- $a Papadimitriou, Konstantinos $u Department of Medical Oncology, University Hospital of Antwerp, Antwerp, Belgium
- 700 1_
- $a Corradini, Stefanie $u Department Radiation Oncology, University Hospital, LMU Munich, Germany
- 700 1_
- $a Popovic, Lazar $u Department Medical Oncology,Oncology Institute of Vojvodina, University of Novi Sad, Serbia
- 700 1_
- $a Kopecky, Jindrich $u Department Oncology and Radiotherapy, Charles University, Hradec Králové, Prague, Czech Republic
- 700 1_
- $a Rodriguez, Andres $u Medical Oncology, Instituto Alexander Fleming in Buenos Aires, Buenos Aires, Argentina
- 700 1_
- $a Antunac, Katarina $u University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
- 700 1_
- $a Yi, Junlin $u Department Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
- 700 1_
- $a Lovey, Jozsef $u National Institute of Oncology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Strojan, Primoz $u Department Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia
- 700 1_
- $a Saraireh, Haytham $u Department Radiation Oncology, Royal Medical Service, Amman, Jordan
- 700 1_
- $a Røtterud, Ranveig $u Cell Biologist, CEO Bladder Cancer, Oslo, Norway
- 700 1_
- $a Chojnacka, Marzanna $u Department of Oncology and Radiotherapy, Maria Skłodowska- Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Olalla, Santa Cruz $u Service de Radio-Oncologie, Neuchâtel Hôpital Network, La Chaux-de-Fonds, Switzerland
- 700 1_
- $a Chilingirova, Natalia $u Department Medical Oncology, Center of Excellence, Heart and Brain Hospital Pleven, Medical University Pleven, Bulgaria
- 700 1_
- $a De Mello, Ramon Andrade $u Department Medical Oncology Escola Paulista de Medicina, Federal University of São Paulo, Brazil $u Department Biomedical Sciences,and Medicine, University of Algarve, Faro, Portugal
- 700 1_
- $a Amaral, Giovanna Araujo $u Department Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo, Brazil
- 700 1_
- $a Arbabi, Farsid $u Department Medical Oncology, Rooshana Cancer Center, Tehran, Iran
- 700 1_
- $a Vidra, Radu $u Medical Oncology, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. O. Fodor", Cluj-Napoca, Romania
- 700 1_
- $a Rapushi, Erjeta $u Department Medical Oncology, Berat Regional Hospital, Berat, Albania
- 700 1_
- $a Takeuchi, Dan $u Matsudo City General Hospital, Chiba, Japan
- 700 1_
- $a Christopoulos, Chirstos $u Service de Radiothérapie Oncologique, GHT Grand Paris Nord-Est. G.H.I Le Raincy -Montfermeil, France
- 700 1_
- $a Ivanova, Irina $u Murmansk Branch of All-Russian Association of Cancer Patients "Zdravstvuy", NGO Center of Initiatives Support, Murmansk, Russia
- 700 1_
- $a Djan, Igor $u Department for Radiosurgery and SBRT, Clinical center of Serbia, Belgrade, Serbia
- 700 1_
- $a Petricevic, Branka $u Department of Medical Oncology and Hematology,Wilhelminenspital, Vienna, Austria
- 700 1_
- $a Cellini, Francesco $u Radioterapia Oncologica-Fondazione Policlinico A. Gemelli, IRCCS -Rome, Italy
- 700 1_
- $a Mihaylova, Iglika $u Department of Radiotherapy,Specialized Hospital for Active Treatment in Oncology "Plovdivsko pole", Sofia, Bulgaria
- 700 1_
- $a Plavetic, Natalija Dedic $u Department of Oncology, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Kuhar, Cvetka Grašič $u Department Medical Oncology, Institute of Oncology, Ljubljana, Slovenia
- 700 1_
- $a Takeuchi, Elena $u The Christie NHS Foundation Trust, Manchester, UK
- 700 1_
- $a Kountourakis, Pantelis $u Department Medical Oncology,Bank of Cyprus Oncology Centre, Nicosia, Cyprus
- 700 1_
- $a Ntellas, Panagiotis $u Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
- 700 1_
- $a Gazouli, Ioanna $u Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
- 700 1_
- $a Gkoura, Stefania $u Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
- 700 1_
- $a Yuce, Salih $u Chairmen of the Board-Young Saving Association, Turkey
- 700 1_
- $a Er, Özlem $u Acıbadem University, Faculty of Medicine, Turkey
- 700 1_
- $a Yasmina, Chait $u Service de Haematologie, GHT Grand Paris Nord-Est. G.H.I Le Raincy -Montfermeil, France GHT Grand Paris Nord-Est, G.H.I Le Raincy -Montfermeil, France
- 700 1_
- $a Kumaran, Gireesh $u Medical Oncology, Auckland Regional Cancer and Blood Service, Auckland, New Zealand
- 700 1_
- $a Spahiu, Orges $u Radiation Therapy Unit, University Hospital Center "Mother Teresa", Tirana, Albania
- 700 1_
- $a Yusuf, Aasim $u Gastroenterology, Acting CEO Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore and Peshawar Pakistan
- 700 1_
- $a Gono, Paulina $u ECPC Partneships and Communication Officer, Belgium
- 700 1_
- $a Apostolidis, Kathi $u ECPC President ,Belgium
- 700 1_
- $a Tolia, Maria $u Department. Radiation Oncology, University Hospital of Heraklion, Crete, Greece
- 773 0_
- $w MED00209440 $t Reviews on recent clinical trials $x 1876-1038 $g Roč. 17, č. 1 (2022), s. 11-14
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34967300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135805 $b ABA008
- 999 __
- $a ok $b bmc $g 1822981 $s 1170832
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 17 $c 1 $d 11-14 $e - $i 1876-1038 $m Reviews on recent clinical trials $n Rev Recent Clin Trials $x MED00209440
- LZP __
- $a Pubmed-20220720
